278 related articles for article (PubMed ID: 23242595)
1. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Dimopoulos MA; Delforge M; Hájek R; Kropff M; Petrucci MT; Lewis P; Nixon A; Zhang J; Mei J; Palumbo A
Haematologica; 2013 May; 98(5):784-8. PubMed ID: 23242595
[TBL] [Abstract][Full Text] [Related]
2. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Dimopoulos MA; Palumbo A; Hajek R; Kropff M; Petrucci MT; Lewis P; Millar S; Zhang J; Mei J; Delforge M
Leuk Lymphoma; 2014 Jul; 55(7):1489-97. PubMed ID: 24144308
[TBL] [Abstract][Full Text] [Related]
3. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Delforge M; Minuk L; Eisenmann JC; Arnulf B; Canepa L; Fragasso A; Leyvraz S; Langer C; Ezaydi Y; Vogl DT; Giraldo-Castellano P; Yoon SS; Zarnitsky C; Escoffre-Barbe M; Lemieux B; Song K; Bahlis NJ; Guo S; Monzini MS; Ervin-Haynes A; Houck V; Facon T
Haematologica; 2015 Jun; 100(6):826-33. PubMed ID: 25769541
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Falco P; Cavallo F; Larocca A; Rossi D; Guglielmelli T; Rocci A; Grasso M; Siez ML; De Paoli L; Oliva S; Molica S; Mina R; Gay F; Benevolo G; Musto P; Omedè P; Freilone R; Bringhen S; Carella AM; Gaidano G; Boccadoro M; Palumbo A
Leukemia; 2013 Mar; 27(3):695-701. PubMed ID: 22996335
[TBL] [Abstract][Full Text] [Related]
7. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Stewart AK; Jacobus S; Fonseca R; Weiss M; Callander NS; Chanan-Khan AA; Rajkumar SV
Blood; 2015 Sep; 126(11):1294-301. PubMed ID: 26157076
[TBL] [Abstract][Full Text] [Related]
8. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
9. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
11. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
12. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Nielsen LK; Stege C; Lissenberg-Witte B; van der Holt B; Mellqvist UH; Salomo M; Bos G; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden A; Deenik W; Coenen J; Hinge M; Klein S; Tanis B; Szatkowski D; Brouwer R; Westerman M; Leys R; Sinnige H; Haukås E; van der Hem K; Durian M; Gimsing P; van de Donk N; Sonneveld P; Waage A; Abildgaard N; Zweegman S
Haematologica; 2020 Jun; 105(6):1650-1659. PubMed ID: 31515355
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
Kristinsson SY; Landgren O; Rajkumar VS
Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS
Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
White DJ; Bahlis NJ; Marcellus DC; Belch A; Stewart AK; Chen C; Kovacs MJ; Macdonald DA; Reece DE; Reiman T; Harnett E; Meyer RM; Chapman JA; Couban S
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):19-24. PubMed ID: 23141150
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Bringhen S; D'Agostino M; Paris L; Ballanti S; Pescosta N; Spada S; Pezzatti S; Grasso M; Rota-Scalabrini D; De Rosa L; Pavone V; Gazzera G; Aquino S; Poggiu M; Santoro A; Gentile M; Baldini L; Petrucci MT; Tosi P; Marasca R; Cellini C; Palumbo A; Falco P; Hájek R; Boccadoro M; Larocca A
Haematologica; 2020 Jul; 105(7):1937-1947. PubMed ID: 31582542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
